Together, these findings show that AR-R17779 has an antitumorigenic effect in multiple models of immune-competent breast cancer that led us to consider whether this therapeutic approach was relevant to our studies on the expression of CHRNA7 observed in myeloid immune cells from the previous studies. The gene discussed is CHRNA7; the disease is breast carcinoma.